# A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

> **NCT07348237** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (estimated)

## Conditions studied

- Chronic Kidney Failure
- End-Stage Renal Disease
- Renal Impairment

## Interventions

- **DRUG:** MK-2828

## Key facts

- **NCT ID:** NCT07348237
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2026-08-18
- **Final completion:** 2026-08-18
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348237, "A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07348237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*